NFE2L2 and neoplasm: The presence of mutations of common oncogenes such as BRAF, MYC, and KRAS can increase NRF2 transcription and activity in malignant cells and save tumor cells from the ROS cytotoxicity caused by chemotherapeutic agents such as cisplatin and play a key role in drug resistance mechanisms[60,61].